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CARDIOLOGY

Omega-3 Fatty Acid
Consumption
in the
Reduction of
Sudden
Cardiac Death:

A Critical Appraisa
Katie J. Walker, MS, RN, FNP; A. Elaine Bond, DNSc, APRN, CCRN;
Renea L. Beckstrand, PhD, RN, CCRN; and Mary Williams, PhD, RN
This article examines the effects
of omega-3 fatty acid consumption in reducing sudden cardiac
death risk, and provides useful
dosing recommendations
for
patients—with or without a history of coronary heart disease—
in a primary care practice.

S

udden cardiac death causes
approximately 300,000 persons in the tJnited States to
die each year, as well as millions
more worldwide.' Mortality statistics in the United States and the
United Kingdom show that up to
80% of sudden cardiac deaths are
attributed to ventricular fibrillation
VOL. 10 N O . 1 1 / 1 2

(VF).^ Although VF and other fatal consumption is needed to detercardiac dysrhythmias can be treat- mine whether such consumption
ed in a variety of ways, VF preven- might reduce sudden cardiac death
tion is even more advantageous. or a hypothesized predictor of sudResults of many epidemiologic den cardiac death—heart rate varistudies, human intervention trials, ability (HRV).
and animal experiments have sugN-3 fatty acids and n-6 fatty
gested that consuming omega-3 acids are essential fatty acids, mean(n-3) fatty acids through diet or ing that the human body cannot
dietary supplements may decrease manufacture them and must obtain
sudden cardiac death, primarily by them through dietary means.
decreasing the risk of fatal cardiac Alpha-linolenic acid (ALA), a prearrhythmias.''^ However, these cursor to n-3 fatty acids, must also
studies were not randomized con- be acquired through diet. When
trolled trials (RCTs)—the gold ALA is ingested, the body metabostandard for evidence-based prac- lizes it into either eicosapentaenoic
tice decisions. Therefore, an analy- acid (EPA) or docosahexaenoic add
sis of RCFs evaluating n-3 fatty acid (DHA), either of which is more
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readily used by the body. EPA and
DHA are found primarily in oily
fish, whereas ALA is highly concentrated in certain plant oils (eg,
flaxseed oil) and in nuts.^''
N-3 and n-6 fatty acids are
types of polyunsaturated fatty
adds, or PUFAs. It is important to
maintain an appropriate balance
of n-3 and n-6 fatty acids in the
diet, because these two substances
work in a check-and-balance fashion. N-3 fatty acids help reduce
inflammation at the cellular level,
whereas n-6 fatty acids tend to promote cellular inflammation."
Although inflammation is essential to the healing process, unchecked inflammation causes
secondary damage. An inappropriate balance of n-6 and n-3 fatty
acids contributes to the development of inflammatory diseases
such as lupus, rheumatoid arthritis, and asthma, whereas a proper
balance helps maintain, and even
improve, physical health. A healthful diet should consist of roughly 2
to 4 times more n-6 fatty acids
than n-3 fatty acids.^' However, the
typical "American" diet contains 11
to 30 times more n-6 fatty acids
than n-3 fatty acids. Many researchers believe that this dietary
imbalance is a major factor in the
rising rate of inflammatory disorders in this country.'''
Marine vertebrates (ie, flsh) are
a major source of n-3 fatty acids.
When a person eats fish, n-3 fatty
acids accumulate in the phospholipid bi-layer of cell membranes,
especially those of the heart.'
Researchers have hypothesized that
this accumulation of n-3 fatty acids
in these cell membranes changes
the depolarization threshold of
cardiac myocytes, as well as lengthening the relative refractory time.'
In particular, when cardiac tissue
becomes ischémie, in the absence

of an accumulation of n-3 fatty
acids in the cell membranes, cells
will rapidly become ischémie,
which leads to cell death. These
ischémie cells are deficient in
adenosine tri-phosphate, the energy source for the active sodiumpotassium pump, which then
becomes dysfunctional. As a result,
the interstitial potassium level rises
(cells cannot absorb a normal
amount of potassium without a
functionally active sodium-potassium pump). This increase in interstitial potassium raises the resting
membrane potential of cells surrounding the ischémie tissue and
narrows the distance to threshold,
making these cells hyperexcitable.
These hyperexcitable cells depolarize with minimal stimulus. When
depolarization occurs at vulnerable moments during normal cardiac electrical cycles, dysrhythmias
are initiated. In the presence of cardiac cells saturated with n-3 fatty
acids, by contrast, this hyperexcitable state of surrounding cardiac
tissue does not occur." '°

Purpose
The purpose of this critical
appraisal was three-fold: (1) to
conduct a thorough search for
RCTTs that address the consumption of n-3 fatty acids in preventing
sudden cardiac death and HRV, (2)
to critically appraise these identified
studies using the Boyack and
Lookinland Methodological Quality
Index (MQI)," and (3) to make dinical recommendations regarding
consumption of n-3 fatty acids as a
means to decrease the inddence of
sudden cardiac death.

Methodology
Identification of Studies—An
elertronic search was conduaed to
identify studies from 1994 to 2005

in the following databases: Alternative Health Watch, Biomédical
Reference Collection: Comprehensive, CINAHL, Medline, Health
Business Fulltext Elite, Nursing &
Allied Health Collection, Comprehensive Cochrane Database of
Systematic Reviews, and Cochrane
Controlled Trials Register. Search
terms used were omega-3 fatty
adds, heart disease, arrhythmias,
dysrhythmias, ventricular fibrillation, double-blinded, RCT, human,
adult, and sudden cardiac death.
The search was limited to RCTs
published in English. A total of
14 articles meeting these criteria
were found in the electronic
search. References from all articles were reviewed for possible
additional RCTs.
Inclusion Criteria—For inclusion in the critical review, studies
needed to focus on the prevention
of sudden cardiac death in humans
by using supplemental or dietary
n-3 fatty acids. No dosage range was
specified. Participants were aged 18
years or older. Partidpants in six of
the studies were included specifically because of present or prior coronary heart disease (CHD) status,
whereas two studies evaluated partidpants without documentation of
CHD to assess the effects of n-3 fatty
acids on HRV.
Exdusion Criteria—Studies were
excluded if subjects had undergone
coronary artery bypass surgery or if
the studies focused mainly on n-3's
effects in patients with hyperlipidemia. Based on these criteria, 6 of
the originally identified 14 articles
were excluded.
Data Extraction—Two independent reviewers extracted data
from the RCT articles using the previously tested Boyack and Lookinland MQI as the standard." Data
were logged into a table format
and each study received a score
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based on its MQI quality. To
increase inter-rater reliability, both
author and co-author first analyzed an RCr document (not one
of the studies in the review) using
the same MQI tool. Both reviewers
resolved any differences in rating
by discussing the article in question and reaching consensus.
Description of RCT Methodological Quality Assessment—
Each RCT's compliance with standards set forth in the MQI was
assessed. The final evaluation
score for each RCT was presented
as a percentage ofthe total possible score. Scores ranged from 0%,
representing a total lack of adherence to MQI standards, to 100%,
representing perfect adherence to
all MQI standards. No standard
regarding an acceptable score versus an unacceptable score was
set, although as a score moved
closer to 100%, the more
methodologically sound the
study became. To calculate the
MQI percentage, the total possible score was divided into the
individual score of an RCT. If any
méthodologie criterion in the
MQI was deemed nonapplicable
to the study, the denominator of
the MQI was reduced and the
total score was adjusted and
recalculated accordingly."

Duration of the studies ranged
from 12 weeks to 4 years. Three
studies lasted for 12 weeks."^"'*
Several studies limited the subject
population to a single ethnici-

Treatment Characteristics—The
amount of n-3 consumption varied widely. For the studies using
supplements, patients consumed
1 to 6.6 grams daily for the dura^12,11,1518 ^ j studies were conducted tion of the study"""""'" Some
in European countries; none studies used natural foods as the
reported using US subjects.
source of n-3 fatty acids;'^'^ as
Funding sources were unreport- such, serving amounts were diffied in three studies.*"""" Two studies cult to quantify. In DART (Diet and
were funded by pharmaceutical Reinfarction Trial), a landmark
companies,'"'' and the remaining study, participants consumed apthree studies received funding proximately 2.5 grams of EPA
from non-pharmaceutical-affiliat- (equivalent to about 300 grams of
ed sources.'^"''^
fish) every week.'^ This amount and
Four studies were single-center dosing frequency were much less
trials.'^"""' It is generally accepted than those used in the other RCTs.
that multicenter trials reduce the In the Lyon Diet Heart Study,
chance for bias and increase sample patients received fatty acids from
diversity. Four of the five top-rank- legumes (20 g/day), the primary
ing studies that supported n-3 con- source of ALA, and fish (46.5 g/day),
sumption as an effective treatment the primary source of EPA.'^ The
for sudden cardiac death reducfion intake of 46.5 grams daily of fish
were multicenter investigations.'^ '"' equaled just less than 0.5 grams
Patient Characteristics—In all daily of n-3 fatty acids. Again, the
studies combined, patient age broad range of dietary n-3 PUFA
ranged from 27 to 75 years. One dosages among different studies
study reported that participants made it difficult to ascertain the
were aged 50 to 70 years," and three exact amounts that subjects ingeststudies reported that participants ed. The CISSI (Cruppo Italiano per
were less than 70 or 75." '"' In one la Sperimentazione della Streptostudy, subjects ranged in age from chinasi nell'Infarto Miocardico)27 to 49, which is substantially Prevenzione Study used a prelower than the age groups enrolled scription-strength omega-3 prodin the other studies." The age ua (Omacoi<s) 1 g daily, as opposed
group in this study also had the to an over-the-counter dietary suplowest sudden cardiac death risk plement."" (Outside the United
when compared with subjects in States, Omacor is indicated for secResults
ondary prevention in MI survivors
Study Characteristics—Eight of the other studies.
the originally identified 14 articles
Two studies enrolled subjects and for management of hyperwere systematically reviewed. All without previous documentation triglyceridemia; in the United
studies were RCTs. One article pub- of CHD to assess the effects of n-3 States, it is approved by the Food
lished in 1989 was included as a fatty acids on HRV, a hypothesized and Drug Administration for the
landmark article.'' The other stud- predictor of sudden cardiac latter indication only.'')
ies were published between 1994 death.'" Six studies enrolled subThe diet followed in the Lyon
and 2005. MQI scores, along with jects who had a history of myocar- study, identified as a Cretan
design and treatment details and dial infarction (MI), usually within Mediterranean diet, was rich in
specific study strengths and weak- the past 6 months." '^'='"
vegetables, fruits, antioxidants,
nesses, are outlined in Table l/''^'"
Several studies did not include fish, legumes, and grains.''' The
MQI scores ranged from 52% to gender demographics.""'^'" One margarine used by the study partic91%, with a mean score of 69%.
study enrolled males only.'^
ipants was ALA enriched as well.
VOL, 10 N O , 1 1 / 1 2
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Although the amounts of ALA,
EPA, or DHA found in these types
of food were not stated and were
therefore difficult to quantify, it is
generally accepted that 50 grams of
fatty fish contain approximately
0.5 grams of n-3 PUFAs.
The Cretan Mediterranean diet
had a complex combination of
foods that might have contributed
to the overall decrease in sudden
cardiac death noted in the experimental group. The credit for reduction in sudden cardiac death could
not be exclusively attributed to
increased consumption of ALA and
EPA/DHA because, with the complex dietary combination, it was
impossible to eliminate confounding variables. However, it is probable that the consumption of ALA
and EPA/DHA played a large role
in the reduction of sudden cardiac
death, based on subjects' blood
level analyses. During the study,
blood was drawn to measure the
fatty acid composition of platelets,
a sensitive and specific indicator of
effective dietary intake of n-3
PUFAs.'^ It was found that subjects
on the Cretan Mediterranean diet
had higher levels of n-3 PUFAs
than did the control group.
Clinical Outcomes—All studies

that used sudden cardiac death as a
major end point showed a decrease
in sudden cardiac death in experimental groups consuming 2.5
grams weekly to 6.6 grams daily of
n-3 fatty acids or n-3 fatty acid precursors (ALA) in diet or supplement form."'"" One of these
studies failed to report findings
with an appropriate degree of significance (P <0.05).'»
Outcomes varied in studies that
used HRV as the major end point.
One study showed a decrease in
HRV in experimental group participants who consumed supplemental n-3 PUFAs." The other two

studies did not show a difference
in HRV between the experimental
group and the control group.'^'•'
However, one study further analyzed the data and found a significant difference between male and
female participants, and concluded that HRV decreased in male
participants but not in female
participants." No P value was
reported in this study. These three
studies lasted 12 weeks and either
did not report the performance of
a power analysis or did not meet
power analysis criteria.'^'"" All n-3
PUFAs consumed in these studies
were in supplement form.
Dosages, as well as the benefits
of active treatment, varied considerably among the studies. For
example, DART showed a 29%
reduction in sudden cardiac death
between the treatment group (~2.5
g/week of dietary n-3 PUFAs) and
the control group.'^ The Lyon study
showed an 81% difference in sudden cardiac death between participants consuming approximately
2.75 grams weekly of n-3 PUFAs
and an unspecified amount of ALA
and those who did not incorporate
these nutrients to the same extent
in their diet." The CISSI studies
showed a 45% reduction in sudden cardiac death in the treatment
group consuming 1 g daily of n-3
gelatin capsules.""'' Of interest,
these studies—DART, the Lyon
study, and the GISSI studies—
showed no relationship between
n-3 dosage and the percentage of
sudden cardiac death risk reduction. These three studies lasted 2
to 4 years, had large sample sizes,
and had results that were clinically
significant.
The average MQI score of the
studies that showed a positive correlation between n-3 fatty acid
consumption and sudden cardiac
death prevention was 72% (range.

59%-91%).'"""' The two lowest
MQI scores were earned by a study
that found no differences among
groups consuming n-3 fatty acids
or n-3 fatty acid precursors (ALA)
and a control group (MQI score,
62%)'^' and by a study that showed
no difference in HRV between
women in an experimental group
who consumed n-3 fatty acids versus those in a control group who
did not consume n-3 fatty acids
(MQI score, 52%);'* these two
studies had an average MQI score
of 57%.
Therefore, based on MQI scores,
studies showing n-3 fatty acids to
be effective in preventing sudden
cardiac death were of higher
méthodologie quality than were
studies showing n-3 fatty acids to
be ineffective in this regard. No
study reported that n-3 fatty acid
treatment was detrimental, either
in terms of increasing sudden cardiac death risk or in having serious
side effects.
The CISSI studies found significant decreases in sudden cardiac
death among experimental groups
consuming n-3 fatty acids at 8
weeks.'^'^ These results support other
study findings showing decreases in
HRV in subjects consuming n-3 fatty
acids afier 12 weeks."" Of note,
these studies were performed on a
population with documented CHD,
which may be more sensitive to the
beneficial effects of n-3 fatty acid
consumption. Based on these studies, it is unknown whether n-3 fatty
acid consumption might decrease
the rate of sudden cardiac death in
populations without documented
heart disease.

Discussion
Limitations—When subjects are
dravsm fTom limited ethnic groups,
results cannot necessarily be generalized to all ethnicities. Because six
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ofthe eight studies were conducted
on specific ethnic groups (French,
Danish, Eastern Indian, Italian),"'*
it is difficult to apply these results to
other populations.
Four studies were single-center,
not multicenter, investigations. It is
generally accepted that multicenter
trials reduce the chance for bias by
increasing the diversity of the sample, as well as increase the ability to

TABLE 1

generalize study results. However,
four of the five top-ranking studies
that supported n-3 fatty acid consumption as an effective treatment
for sudden cardiac death reduction
used a multicenter design.'^ '^"
Funding from drug companies
in the CISSI trials may have introduced bias."^'^ In addition, the possibility of other studies' obtaining
funding through pharmaceutical

company-affiliated sources may
weaken the results.'""'
Studies with a longer duration
of treatment ranked higher on the
MQI scale and reported outcomes
related to sudden cardiac death
incidence rather than electrocardiogram readings.'^'^^"'" In addition,
different end points made it difficult to compare the studies with
each other. Three studies used HRV

N-3 FATTY ACID RCTs: GENERAL CHARACTERISTICS'

AUTHORS

DESIGK/TREATMENT

OUTCOMES

PATIENT
CHARACTERISTICS

MQI SCORE/
STRENGTHS/WEAKNESSES^

Geelen et a!

N (toto!) = 84;
n-3 1.5 g/day (n = 42);
p!acebo (n = 42)

-HRV as assessed
by 24-hour ECG
monitoring

50- to 70-year-old
healthy men and v/omen

62%
Strengths: Power analysis
performed. Method of blinding
subjects explicitly stated.
Weaknesses: CI included 0. Not a
multicenter study. Outcomes based
on minimal ECG changes.

N (total) = 2033;
fis!i advice (n= 1015);
no fish advice (n = 1018)

-Sudden cardiac
deoth

Men <70 years with
history of previous Ml

65%

N (total) = 49;
n-3 5.2 g/day (n = 26);
o!ive oi! capsule (n = 23]

-HRV as assessed
by 24-hour ECG
monitoring

Previous non-fatal Ml.
Ejection fraction <40%;
<75 years old. Excluded
patients with pacemakers or
permanent tachyarrhythmias,
and those with serious
noncardiac disease.

68%
Strength: CI did not include zero.
Weaknesses: Performed a power
analysis—however, did not meet
criteria. Short duration of therapy.
Sma!l effect size. All participants
were from Denmark. Not a
mu!ticenter study.

N = 60 (25 women and
35 men), divided into 3
treatment/control groups:
n-3 6.6 g/day x 12 v/ks;
n-3 2.0 g/day x 12 w!<s;
placebo (olive oil)

-HRV as assessed
by 24-hour ECG
monitoring

No documented heart disease.
Men aged 28-48 years and
women aged 27-49 years

52%

2002'

Burr et a! 1989''

Christensen et al
1996'^

Christensen et al
1999"
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Strengths: Power analysis
reported and met. CI did not
include 0. Moderate significance
in effect size.
Weaknesses: No statement of
financial disclosure. Subjects
were not blinded to treatment.
Al! participants were male.

Strengths: No participants
dropped out. No adverse effects
of treatment, and clear
concealment for assessment of
outcome. Analyzed men and
women separate!y.
Weaknesses: Sma!l sample size.
Short durotion of study. Outcomes
based on minimal ECG changes.

VOL.10

NO. 11/12

to predict sudden cardiac death
risk,"^ •'* whereas five studies used
sudden cardiac death as the primary end point. Again, HRV measured
by 24-hour Holter monitoring is a
hypothesized predictor of sudden
cardiac death risk. Variations in
study duration hindered the reliability of comparisons among studies, although it is generally
recognized that dietary changes yield

results quickly Researchers still need
to study long-term outcomes (>12
weeks' duration) to strengthen study
condusions.
The amount of n-3 fatty acids
consumed in each study varied
considerably. This wide discrepancy in dosage amounts makes it difficult to make a concrete dietary
recommendation regarding n-3
fatty acid intake.

Different ages and cardiac
health history in study subjects
may have had a major effect on
study outcomes. One study was
performed on subjects ranging in
age from 27 to 49 years and who
had no history of CHD—a substantially lower age group with a
lesser degree of sudden cardiac
death risk when compared with
participants in other studies.'" By

TABLE 1 N-3 FATTY ACID RCTs: GENERAL CHARACTERISTICS
AUTHORS

DESIGN/TREATMENT

OUTCOMES

PATIENT
CHARACTERISTICS

MQI SCORE/
STRENGTHS/WEAKNESSES

De Lorgeril et al
1995'=

N (total) = 584; modified
diet, high levels of ALA,
a precursor to n-3 PUFAs
(n = 289); no dietary
modification (n = 295)

-Sudden cordiac
death
-Nonfatal Ml

Mole and females <70 years
who survived Ml in the past
6 months

91%

Madïioli 1999"

N (total) = 11,32
n-3 PUFA supplement
1 g/d (n = 283Ó);
vitamin E 300 mg/day
(n = 2830); both treatments
(n = 2830); or neither
treatment (n = 2828)

ra
-Nonfatal Ml
-Stroke

Patients v/ho hod recently
(<3 mo) survived an Ml

80%
Strengths: Multicenter national
study. Large sample size. Longterm health outcome reported.
Weaknesses: No pov/er analysis
reported. All subjects were Italian.

Marchioli et al
2002"

N (total) = 11,323,
-Death
divided into 4 groups:
-Nonfatal Ml
n-3 PUFA supplement
-Stroke
1 g/day; vitamin E 300
mg/day; both treatments;
neither treatment. All
groups received optimal
medical and lifestyle advice.

Patients v/ho had recently
(<3 mo) survived an Ml,
(median, 1 ó days post Ml)

72%
Strengths: Cl did not include 0.
Long-term health outcomes
reported.
Weaknesses: Funded by a drug
compony. No power analysis
reported. All subjects were Italian.

Singh et al 1997"

N (total) = 360; n-3
PUFA-EPA 1.08 g/day
in = 122); 2.9 g/day
mustard oil-ALA (n = 120);
placebo (n =118)

-Sudden cardiac
24-hours post Ml
death
-Nonfatal Ml
-Cardiac dysrhythmias

Strengths: Effect size reported
>80. Met pov/er analysis criteria.
Analyzed over a 4-year time
period. Cl did not include 0.
Weaknesses: Single-blind study.

58.6%

I

Strengths: Explicit statement of
blinding strategy. Based on
intention-to-treat onalysis. Statisical methods reported, ond longterm health of subjects reported.
Weaknesses: No power analysis
reported, na discussion of study
limitotions/biases, no disclosure af
funding source. All subjects from
Eastern India.

RCT = randomized controlled trial; MQI = Methodological Quality Index; HRV = heart rate variability; ECG = electrocardiagram; Cl = confidence interval; Ml =
myocardial infarction; ALA = alpha-linalenic acid; PUFA = polyunsaturated fatty acids; EPA = eicosapentaenoic acid.
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contrast, participants in the study
by Ceelen et al ranged in age from
50 to 70 years, although they also
bad no bistory of CHD.* Results
from these two studies sbowed no
cbange in HRV and may suggest
tbat n-3 fatty acid consumption
primarily benefits patients witb
documented beart disease.
A major flaw in many studies'
design was tbe lack of pre-determined effect size. An effect size
quantifies tbe expected intervenfionrelated difference in mean values
between the placebo and treatment
groups. In studies of sbort duration,
it is impossible to say whether tbe
study was of long enougb duration
to detea significant differences or to
sbow no difference between groups
because none of tbe studies bad a
predicted effect size or a post hoc
report of effea size.
Cender may affect n-3 fatty acid
consumption outcomes. Only one
study made separate analyses for
male and female subjeas.'** In addition, one study enrolled men only.'^
Cender may play a major role in tbe
results of tbe otber RCTs. Cenderspedfic analysis needs to be done in
tbe otber studies to determine
wbetber gender affeas the results of
n-3 PUFA consumption in preventing sudden cardiac deatb.
Small sample sizes weakened
tbe results of several RCTs tbat were
analyzed. One study enrolled 25
women and 35 men,'" and another
had a sample of 84 participants.'
Strengths—Altbougb
some

studies were weaker than otbers in Recommendations
terms of duration, four of tbe top Witb MQI scores ranging from
studies lasted 2 to 4 years. Of inter- 52% to 91% (average score, 69%),
est, tbese top-scoring MQI trials some studies of n-3 fatty acid connot only lasted tbe longest, but sumption were more indicative of
tbey also sbowed tbe most signifi- reliable outcomes tban otbers. If
cant decrease in sudden cardiac clinical recommendations can be
deatb in participants wbo con- made, tbey sbould come from tbe
sumed n-3 fatty acids.
top-ranking studies sbowing tbe
Altbougb tbe average number least amount of bias. Tbese includof subjects in eacb study varied ed tbe DART study, tbe LYON
greatly, one study bad 11,324 par- study, and tbe CISSI trial
ticipants." Tbe average number of reports.'^" '' Altbougb tbe study by
participants in studies sbowing sig- Cbristensen et al received an MQI
nificant results was 4280, and tbe score of 68%, it did not bave a
average number of participants in multieenter design and tbe end
studies finding no effect, or no point was not sudden cardiac
effect in women, was 72. Studies deatbbut, ratber, HRV."
baving tbe most subjects were of
Based on tbe studies reviewed,
bigber quality, as measured by tbe n-3 fatty acid consumption signifiMQI. Tbese studies also sbowed tbe cantly reduces tbe risk of sudden
greatest decrease in sudden cardiac cardiac deatb by preventing fatal
deatb risk wben subjects ingested dysrbytbmias in bigb-risk populan-3 fatty acids.""" Despite tbe fact tions—tbat is, in persons wbo bave
tbat many of tbe studied popula- a significant family bistory of CHD
tions were nationality-segregated, and in tbose wbo bave survived an
conclusions were similar: Con- ML A dosage recommendation is
sumption of EPA, DHA, or ALA difficult to make based on tbese
reduced sudden cardiac deatb risk. findings because tbe dose of n-3
In one study, tbe decrease in PUFAs consumed did not necessariHRV in tbe experimental group ly correlate witb tbe percentage of
after just 12 weeks of n-3 fatty acid sudden cardiac deatb reduction. In
treatment suggests tbat tbe benefi- tbe top studies, consumption of
cial effects of n-3 fatty acids occur eitber syntbetic or natural n-3 fatty
quickly.'^ Otber studies found sta- acids was found to be effective.
tistically significant results in sbort Based on patient preference, tbree
time periods—as little as 8 weeks treatment options may deaease tbe
in tbe CISSI trial."" None of tbe risk of sudden cardiac deatb by as
RCTs reported any adverse effects mucb as 81% in at-risk populations
(Table 2). Unfil additional studies
related to n-3 fatty acid treatment.
are conducted and reported, tbese
recommendations cannot necessarily be applied to women or to perTABLE 2 RECOMMENDED N-3 FATTY ACID TREATMENT OPTIONS
sons witbout documented CHD.
•
1 -gram capsule of n-3 PUFAs daily;
Anotber important aspect to
consider
is a person's consumption
• 2.75 grams of n-3 PUFAs consumed in the diet each week; or
of n-6 fatty acids, wbicb can coun•
1.5 to 3 grams of ALA dietary consumption and 0.5 grams of
teract tbe beneficial effects of n-3
n-3 PUFAs daily
fatty acids.'" In tbe LYON study,
PUFA = polyunsaiurated fatty acids; ALA = alpha-linolenic acid.
tbe overall diet in tbe experimental
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group was lower in n-6 fatty acids
as well as higher in n-3 fatty acids."
Thus, an important point for nurse
practitioners (NPs) to address is
the balance between these two
essential fatty acids. More studies
are needed to evaluate the relationship of these two n-3 PUFAs.
The American Heart Assodation
(AHA) has concluded that n-3 fatty
acids benefit persons with healthy
hearts as well as at-risk individuals
(ie, those with CHD). The AHA recommends that everyone eat fatty
fish (eg, mackerel, lake trout, herring, sardines, albacore tuna,
salmon), all of which are high in
EPA and DHA. The association further advocates eating tofu, legumes,
canola, walnuts, and flaxseed to
increase ALA intake.'" AHA recommendations are listed in Table 3.
These recommendations by the
AHA correspond with the conclusions of high-quality RCTs studying
the efficacy of n-3 fatty adds to prevent sudden cardiac death.'-'"'"
However, more studies are needed
to apply thesefindingsto all populations, particularly women and
healthy persons, as well as very sick
persons suffering from chronic diseases such as diabetes, hyperlipidemia, and hypertension. Studies
that ascertain the exact mechanism
of action of n-3 fatty acids within the
body at the cellular level also need

TABLE 3

to be conducted to confirm how not been shown to cause harm.
sudden cardiac death is prevented.
Based on the results ofthe top-scorIn addition, when n-3 fatty acid ing RCTs and on recommendations
consumption cannot be met by from the AHA, three n-3 fatty acid
diet alone, or when individual treatment options are acceptable
preference necessitates synthetic for patients with previously docusupplementation, NPs need to mented CHD (Table 2). Finally for
ensure that patients use high-quali- persons without documented CHD,
ty n-3 fatty acid supplements (ie, the AHA recommends consumpthose that are free of contami- tion of two servings of fish every
nants). Supplements other than week while concurrently eating
those prepared for RCT use have foods rich in ALA. •
not yet been studied for consistency. As such, it is preferable to Katie J. Walker works in the cardioencourage patients to ingest n-3 vascular intensive care unit at Lucile
fatty acids through the diet rather Packard Children's Hospital in Palo
Alto, California. A. Elaine Bond is an
than through supplements.^"
associate professor (retired), Renea L.
Even with what is known now, Beckstrand is an associate professor,
NPs can be comfortable recom- and Mary Williams is an associate
mending omega-3 fatty acid intake dean, all at Brigham Young University
on a daily to weekly basis for patients in Provo, Utah. A. Elaine Bond is also
with documented CHD as safe and a Fulbright Scholar at the University
effective prophylaxis against sudden of Jordan in Amman. The authors
cardiac death. Furthermore, the cost state that they do not have a financial
of treatment is low, and no signifi- interest in or other relationship with
cant adverse risks associated with any commercial product named in this
omega-3 fatty acid consumption presentation.
have been documented.
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